Two Top Stories of NYSE: DURECT Corporation (NASDAQ:DRRX), Array BioPharma Inc. (NASDAQ:ARRY)

DURECT Corporation (NASDAQ:DRRX)

The shares of DURECT Corporation (NASDAQ:DRRX) started off the last trading session with the price of $2.07 while closing the day with the price of $2.14. The shares of DURECT Corporation (NASDAQ:DRRX) Rise 5.94% with the Gain of 0.07 points.

The shares of DURECT Corporation (NASDAQ:DRRX) traded with the day volume of 2.58 Million shares whereas its average trading volume is 798.31 Million.

While analyzing the past performance of the stock we can see that the shares of DURECT Corporation (NASDAQ:DRRX) Gain 13.23% in the last week while rising 91.07% in the last month. Past quarter performance shows the green light with 111.88%. The semi-annual and annual performance shows 29.7% and 132.18% respectively.

Some critical values of the shares of DURECT Corporation (NASDAQ:DRRX) to be discussed here are: the beta which shows the value at 1.68 while Average True Range of DURECT Corporation (NASDAQ:DRRX) demonstrate the value at 0.1. The weekly and monthly volatility of the shares of DURECT Corporation (NASDAQ:DRRX) are indicated at 5.69% and 6.66%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 90.93.

While studying the financial position of the shares of DURECT Corporation (NASDAQ:DRRX), we can see that the Market capitalization of the company is at 317.92 Million. The shares outstanding for the company is 148.56 Million and the shares float stands at 142.13 Million. The income of the company stand at -3700000 while the sales stand at 49.2 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at -0.03, Price to Earnings or P/E is at 0, Price to Sales P/S show the value of 6.46, the Return on Asset ROA stood at -0.076 and the Return on Equity ROE depicted at -0.449 while Return on Investment ROI is at -0.054.


Array BioPharma Inc. (NASDAQ:ARRY)

Array BioPharma Inc. (NASDAQ:ARRY) started its previous trading session at $16.5 and closed at $16.76 showing a Rise of 1.95 Percent.

The Company traded with an average Volume of 3.98 Million whereas, its Day Volume stood at 2.57 Million.

Looking at the performance of the stock, Array BioPharma Inc. (NASDAQ:ARRY) Loss -4.28% in the last week in its shares price and -1.3% in the last month. Quarterly performance shows a green of 53.48 Percent while Semi-Annual and Annual performances shows a 48.45 and 66.43 percent respectively.

Beta for Array BioPharma Inc. (NASDAQ:ARRY) stands at 1.7 while the ATR (average true range) is at 0.75. The Stock’s Weekly and Monthly Volatility is 3.88% and 4.03% respectively showing a RSI value of 47.98.

While studying the financial position of the shares of Array BioPharma Inc. (NASDAQ:ARRY), we can see that the Market capitalization of the company is at 3.62 Billion. The shares outstanding for the company is 215.78 Million and the shares float stands at 206.5 Million.

The Company generated an income of -137000000 and the sales of 139 Million in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $-0.77 a share. P/E (price to earnings) and P/S (price to sales) values are 0 and 26.02 respectively.

The Return on Assets stands at -0.365, ROE shows a value of -1.078 and ROI for Array BioPharma Inc. (NASDAQ:ARRY) is -0.711 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

View all contributions by

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Comment